Myriad Genetics Inc (MYGN.OQ)
10 Mar 2014
|Market Cap (Mil.):||$2,754.78|
|Shares Outstanding (Mil.):||72.97|
(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s) U.S. stock index futures were little changed on Wednesday. Dow Jones industrial average futures were down 0.07 percent at 15,328, S&P 500 futures were down 0.17 percent at 1,740.7 and Nasdaq 100 futures were down 0.03 percent at 3,451.
- Molecular diagnostics company Myriad Genetics Inc said it plans to buy Crescendo Bioscience for $270 million to enter the autoimmune market, and raised its full-year forecast.
Feb 4 - Molecular diagnostics company Myriad Genetics Inc said it plans to buy Crescendo Bioscience for $270 million to enter the autoimmune market, and raised its full-year forecast.
Nov 20 - Myriad Genetics Inc : * Announces second hrd collaboration * Says research collaboration with Biomarin that will use Myriad's novel hrd
Oct 1 - Shares of molecular diagnostics company Myriad Genetics Inc jumped 13 percent in morning trading after the company said the proposed cut in Medicare reimbursement rates for one of its tests was the result of a clerical error.
|Johnson & Johnson (JNJ.N)||$93.45||+0.13|
|Abbott Laboratories (ABT.N)||$39.82||+0.25|
|Bristol-Myers Squibb Co (BMY.N)||$56.14||+0.31|
|Bristol-Myers Squibb Co (BMYMP.PK)||$970.80||+134.39|
|Amgen, Inc. (AMGN.OQ)||$125.40||+3.14|
|Monsanto Company (MON.N)||$113.60||-0.48|
|Merck KGaA (MRCG.DE)||€119.05||+0.35|
|Gilead Sciences, Inc. (GILD.OQ)||$80.23||+0.65|
|Mylan Inc (MYL.OQ)||$53.41||-1.45|
|Allergan, Inc. (AGN.N)||$129.25||+1.26|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Provider: Wright Reports
Provider: New Constructs, LLC
Provider: Pechala's Reports
Myriad Genetics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile